These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 3520988

  • 1. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.
    Vigeral P, Chkoff N, Chatenoud L, Campos H, Lacombe M, Droz D, Goldstein G, Bach JF, Kreis H.
    Transplantation; 1986 Jun; 41(6):730-3. PubMed ID: 3520988
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [Abstract] [Full Text] [Related]

  • 3. Reexposure to OKT3 in renal allograft recipients.
    Mayes JT, Thistlethwaite JR, Stuart JK, Buckingham MR, Stuart FP.
    Transplantation; 1988 Feb; 45(2):349-53. PubMed ID: 3278428
    [Abstract] [Full Text] [Related]

  • 4. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection.
    Norman DJ, Shield CF, Barry J, Bennett WM, Henell K, Kimball J, Funnell B, Hubert B.
    Am J Kidney Dis; 1988 Feb; 11(2):107-10. PubMed ID: 3277400
    [Abstract] [Full Text] [Related]

  • 5. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Mansour ME, Melvin DB.
    J Heart Transplant; 1989 Feb; 8(5):371-80. PubMed ID: 2529358
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L, Narvarte J, Ackermann J, LeFor W, Weinstein S, Wright C, deQuesada A, Baxter J, Shires D.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [Abstract] [Full Text] [Related]

  • 9. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
    D'Alessandro AM, Pirsch JD, Stratta RJ, Sollinger HW, Kalayoglu M, Maki DG, Belzer FO.
    Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
    [Abstract] [Full Text] [Related]

  • 10. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
    Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D.
    Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
    [Abstract] [Full Text] [Related]

  • 11. One-month prophylactic use of OKT3 in cadaver kidney transplant recipients.
    Debure A, Chkoff N, Chatenoud L, Lacombe M, Campos H, Noël LH, Goldstein G, Bach JF, Kreis H.
    Transplantation; 1988 Mar; 45(3):546-53. PubMed ID: 3279578
    [Abstract] [Full Text] [Related]

  • 12. Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.
    Meijer RT, Surachno S, Yong SL, Bemelman FJ, Florquin S, Ten Berge IJ, Schellekens PT.
    Clin Exp Immunol; 2003 Sep; 133(3):485-92. PubMed ID: 12930378
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection.
    Norman DJ, Shield CF, Barry JM, Henell K, Funnell MB, Lemon J.
    Nephron; 1987 Sep; 46 Suppl 1():41-7. PubMed ID: 3306424
    [Abstract] [Full Text] [Related]

  • 14. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation.
    Millis JM, McDiarmid SV, Hiatt JR, Brems JJ, Colonna JO, Klein AS, Ashizawa T, Hart J, Lewin K, Goldstein LI.
    Transplantation; 1989 Jan; 47(1):82-8. PubMed ID: 2521409
    [Abstract] [Full Text] [Related]

  • 15. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection.
    Thistlethwaite JR, Cosimi AB, Delmonico FL, Rubin RH, Talkoff-Rubin N, Nelson PW, Fang L, Russell PS.
    Transplantation; 1984 Dec; 38(6):695-701. PubMed ID: 6390834
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ.
    Transplantation; 1997 Jul 27; 64(2):274-81. PubMed ID: 9256187
    [Abstract] [Full Text] [Related]

  • 18. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ, Benvenisty AI, Cianci J, Hardy MA.
    Am J Kidney Dis; 1989 Nov 27; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [Abstract] [Full Text] [Related]

  • 19. [The clinical effect of ATG and OKT3 on the treatment of refractory rejection after cadavaric kidney transplantation].
    Ao J, Li Y, Xiao X, Yang W.
    Zhonghua Wai Ke Za Zhi; 1998 Sep 27; 36(9):542-4. PubMed ID: 11825460
    [Abstract] [Full Text] [Related]

  • 20. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM, Goldfarb DA, Fairchild R, Modlin CS, Fisher R, Mastroianni B, Boparai N, O'Malley KJ, Cook DJ, Novick AC.
    Transplantation; 2000 Jun 15; 69(11):2374-81. PubMed ID: 10868643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.